ClinicalTrials.gg
CompletedNCT04453137Updated May 4, 2022

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Adalimumab originator and Adalimumab biosimilar in Plaque Psoriasis, sponsored by Alvotech Swiss AG. Completed at 25 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
4th of 48
567 · median 148
Started
2020
the only one that year
Phase 3
26 of 48
1 open now
Registered
39th of 48
by date
Lead sponsor
2 of 48
Alvotech Swiss AG

Among the 48 studies testing adalimumab in Psoriasis, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 26 in phase 3, and was the 39th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group study to evaluate PK, efficacy, safety, and immunogenicity between patients with moderate to severe chronic plaque psoriasis receiving Humira and patients with moderate to severe chronic plaque psoriasis undergoing repeated switches between Humira and AVT02, followed by an optional safety Extension Phase.

AVT02-GL-302 study is composed of 3 parts:

LeadIn Period: Week 1-12 - OpenLabel Treatment Switching Module: Week 12-28 - DoubleBlind Treatment Optional Extension Phase: Week 28-52 - OpenLabel Treatment

Lead-In Period:

After successfully completing Screening activities, patients will be enrolled in the LeadIn Period.

During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.

Switching Module:

Group 1: patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:

Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections), Sw2-Humira (40 mg every other week) for 4 weeks (2 injections), Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections). Group 2: patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections) The last study treatment administration in the Double-Blind Switching Module is at Week 26. The last study assessment is at Week 28 for both groups. The end-of-study (EoS) visit for the interchangeability (IC) part of study is planned at Week 28 (ie, 2 weeks after the last study treatment administration, EoS IC).

Extension Phase:

At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.

The clinical study report (CSR) for the IC part of the study will include the data from the OpenLabel Lead-In Period and Double-Blind Switching Module.

The Extension Phase CSR will include the data from the additional 24-week Open-Label Extension Phase (Weeks 28 to 52).

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has signed the form and documentation as required by relevant competent authorities and is able to understand and adhere to the visit schedule and study requirements.
  2. Patient is male or female aged 18 to 75 years, inclusive, at the time of Screening.
  3. Patients with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians Global Assessments (sPGA) ≥ 3 (moderate) at Screening and at Baseline (Week 1/Day 1).
  4. Patient has had stable disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).
  5. Patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
  6. Patient is naive to adalimumab therapy, approved or .
  7. Patient has a negative QuantiFERON test for tuberculosis (TB) during Screening. Note: Patients with an indeterminate QuantiFERON test are allowed if they have all of the following:

    1. No evidence of active TB on chest radiograph within 3 months prior to the first dose of study drug.
    2. Documented history of treatment of TB or adequate prophylaxis initiation with an isoniazid-based regimen > 1 month prior to receiving study drug in accordance with local recommendations.
    3. No known exposure to active TB after most recent prophylaxis.
    4. Asymptomatic at Screening and Baseline. Investigators should check with the medical monitor before enrolling such subjects.
  8. Women of (except those who are for more than 2 years or if surgically sterile) must have a negative serum pregnancy test during Screening and negative urine pregnancy test at Baseline (Week 1/Day 1).
  9. Sexually active women of childbearing potential must agree to use highly effective (sterilization, hormonal contraception pills or injection or implants, sterilization and abstinence) for the duration of the study and until 6 months after the last dose of the study drug. Male patients must agree to use contraception for the duration of the study and agree not to donate sperm during and for 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study treatment of psoriasis.
  2. Patient has prior use of any of the following medications within specified time periods or will require use during the study:

    1. Topical medications within 2 weeks of Baseline (Week 1/Day 1). PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the Baseline (Week 1/Day 1).
    2. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the Baseline (Week 1/Day 1).
    3. Any prior or concomitant adalimumab therapy, either approved or .
    4. Any systemic in the 4 weeks prior to Screening.
    5. Investigational agent(s) within 90 days or 5 half-lives (whichever is longer) before Baseline (Week 1/Day 1) (Refer to the following table for approved/marketed products).

    Specified are as follows:

    • Adalimumab: not allowed
    • Alefacept, Briakinumab, Brodalumab, Golimumab: 24 weeks
    • Ustekinumab: 15 weeks
    • Etanercept , Secukinumab , Infliximab , Certolizumab, Pegol: 12 weeks
    • Cyclosporine: 4 weeks
    • Methotrexate: 4 weeks
    • PUVA-UVA/UVB: 4 weeks
    • Oral retinoid: 4 weeks
    • Corticosteroids IM - IV - oral - intra-articular for psoriatic arthritis: 4 weeks
    • Topical psoriasis treatments (except in face, eyes, scalp, palms, soles, and genital area and except only mild potency steroids in these areas): 2 weeks
  3. Patient has received live or attenuated vaccines during the 4 weeks prior to Screening or intends to receive a live or attenuated vaccine at any time during the study.
  4. Patient has an underlying condition (including, but not limited to, metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) which, in the opinion of the Investigator or designee, significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
  5. Patient has a planned surgical intervention during the duration of the study and which, in the opinion of the Investigator or designee, will put the subject at further risk or hinder the patient's ability to maintain compliance with study treatment and the visit schedule.
  6. Has any active and serious infection or history of infections as follows:

    1. Any active infection:

      • For which non-systemic anti-infective were used within 4 weeks prior to randomization. Note: patients receiving topical antibiotics for facial acne do not need to be excluded.
      • Which required hospitalization or systemic anti-infective within 8 weeks prior to randomization.
    2. Recurrent or chronic infections or other active infection that, in the opinion of the Investigator or designee, might cause this study to be detrimental to the subject.
    3. Invasive fungal infection or mycobacterial infection.
    4. Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis.
  7. Patient is positive for , virus antibody, or surface antigen (HBsAg) and/or is positive for hepatitis B core antibody.
  8. Patient has severe progressive or uncontrolled, disease that in the judgment of the Investigator or designee renders the subject unsuitable for the study.
  9. Patient has a history of within 5 years except for adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
  10. Patient has an active neurological disease, such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, and transverse myelitis, or a history of neurologic symptoms suggestive of central nervous system demyelinating disease.
  11. Patient has moderate to severe heart failure ( [NYHA] Class III/IV).
  12. Patient has a history of to the active substance or to any of the of Humira or AVT02.
  13. Patient is pregnant or nursing (lactating) woman, where pregnancy is defined as the state of a female after conception and until the termination of gestation.
  14. Patient exhibits evidence (as assessed by the Investigator or designee using good clinical judgment) of active substance abuse (alcohol or drugs) within 6 months of Screening that may impact patient's ability to participate in the study.
  15. Is unable to follow study instructions and comply with the protocol in the opinion of the Investigator or designee.
  16. Patient has a history of clinically significant hematological abnormalities, including cytopenias (eg, thrombocytopenia, leukopenia).
  17. Has a laboratory abnormality that, in the opinion of the Investigator or designee, could cause this study to be detrimental to the subject. The following laboratory abnormalities should be carefully considered:

    1. \< 9 g/dL.
    2. count \< 100,000/mm3.
    3. White blood cell count \< 3000 cells/mm3.
    4. and/or alanine aminotransferase that is persistently ≥ 2.5 × the . (Persistently indicates at least on 2 occasions separated by a number of days).
    5. \< 50 mL/min (Cockcroft-Gault formula).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
567 participants (actual)

Study arms

  • Active comparator
    Humira 40 mg/mL (Adalimumab Originator)

    During the LeadIn Period, patients will receive Humira (initial dose of 80 mg \[2 × 40 mg\] administered subcutaneously \[SC\], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index \[PASI\] ≥ 75 \[PASI75\]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.

    Biological: Adalimumab originator

  • Active comparator
    IC - Humira 40 mg/mL (Adalimumab Originator)

    patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)

    Biological: Adalimumab originator

  • Experimental
    IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)

    patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26: * Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections), * Sw2-Humira (40 mg every other week) for 4 weeks (2 injections), * Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections).

    Biological: Adalimumab originator · Biological: Adalimumab biosimilar

  • Experimental
    AVT02 40 mg/mL (Adalimimab Biosimilar)

    At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 \[PASI50\]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.

    Biological: Adalimumab biosimilar

Interventions

  • Subcutaneous injection every other week

    Also known as: Humira

  • BiologicalAdalimumab biosimilar

    Subcutaneous injection every other week

    Also known as: AVT02

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve over the dosing interval from Week 26 to Week 28 (AUCtau,26-28)

    Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUCtau, 26-28) of AVT02 and Humira

    Time frame: Week 26 to Week 28

  2. Maximum concentration over the dosing interval from Week 26 to Week 28 (Cmax, 26-28)

    Venous blood samples will be collected for measurement of serum concentration of AVT02 and Humira

    Time frame: Week 26 to Week 28

Secondary outcomes

  1. Psoriasis Area and severity index

    Percent (%) improvement of PASI from Week 1 to Week 28 and from Week 12 to Week 28

    Time frame: Week 1 to Week 28 and week 12 to Week 28

07

Study locations

25 sites
  • 9901
    Tbilisi, Georgia
  • Alvotech Swiss AG - 9904
    Tbilisi, Georgia
  • Alvotech Swiss AG - Site 9902
    Tbilisi, Georgia
  • Alvotech Swiss AG - Site 9903
    Tbilisi, Georgia
  • Alvotech Swiss AG - Site 3501
    Reykjavik, Iceland
  • Alvotech Swiss AG - Site 4803
    Gdańsk, Poland
  • Alvotech Swiss AG - Site 4804
    Kraków, Poland
  • Alvotech Swiss AG - Site 4807
    Kraków, Poland
  • Alvotech Swiss AG - Site 4806
    Toruń, Poland
  • Wromedica Centrum Zdrowia
    Wrocław, 51-685, Poland
  • Alvotech Swiss AG - 4808
    Wrocław, Poland
  • Alvotech Swiss AG - Site 4805
    Łódź, Poland
  • Alvotech Swiss AG - Site 7001
    Kemerovo, Russian Federation
  • Alvotech Swiss AG - Site 7005
    Krasnodar, Russian Federation
  • Alvotech Swiss AG - Site 7003
    Saint Petersburg, Russian Federation
  • Alvotech Swiss AG - Site 7004
    Saint Petersburg, Russian Federation
  • Alvotech Swiss AG - Site 7006
    Saint Petersburg, Russian Federation
  • Alvotech Swiss AG - Site 7002
    Saratov, Russian Federation
  • Alvotech Swiss AG - Site 3805
    Kharkiv, Ukraine
  • Alvotech Swiss AG - Site 3807
    Kharkiv, Ukraine
  • Alvotech Swiss AG - Site 3801
    Kyiv, Ukraine
  • Alvotech Swiss AG - Site 3806
    Kyiv, Ukraine
  • Alvotech Swiss Ag - Site 3802
    Rivne, Ukraine
  • Alvotech Swiss AG - Site 3804
    Uzhgorod, Ukraine
  • Alvotech Swiss AG - Site 3803
    Zaporizhzhya, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2021, 11 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2020
First posted
Jul 1, 2020
StartActual
Jun 30, 2020
Primary completionActual
May 31, 2021
CompletionActual
Nov 16, 2021
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04453137
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Jun 30, 2020
Primary completion
May 31, 2021
Completion
Nov 16, 2021
Last update
May 4, 2022

Study contacts

Steven Feldman, MD, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion